This iPub^® is sponsored by Amgen Inc.

Join Ajai Chari, MD, to learn more about recent advancements in immuno–oncology and Bispecific T–Cell Engager (BiTE^®) technology.¹ BiTE^® molecules are designed to engage the cytotoxic potential of the body's endogenous T cells to various tumor specific antigens to target and help eliminate detectable cancer cells.^2,3

As a leader in immuno–oncology, Amgen is investigating several BiTE^® molecules as both monotherapy and combination therapy across multiple tumor types with potential versatility in solid and hematologic malignancies.^1,2,4

In this iPub^®, Dr Chari will highlight the investigational target B–cell maturation antigen in MM and the prostate–specific membrane antigen in prostate cancer, as well as emerging targets for investigation with the BiTE^® immuno–oncology platform.⁴

References

1. Yuraszeck T, Kasichayanula S, Benjamin JE. Translation and clinical development of bispecific T-cell engaging antibodies for cancer treatment. Clin Pharmacol Ther. 2017;101(5):634-645.

2. Baeuerle PA, Reinhardt C. Bispecific T-cell engaging antibodies for cancer therapy. Cancer Res. 2009;69(12):4941-4944.

3. Staerz UD, Kanagawa O, Bevan MJ. Hybrid antibodies can target sites for attack by T cells. Nature. 1985;314(6012):628-631.

4. Amgen pipeline. Amgen website. https://www.amgenpipeline.com/-/ media/themes/amgen/amgenpipeline-com/amgenpipeline-com/pdf/ amgen-pipeline-chart.pdf. Accessed September 1, 2020.

5. Cancer progress timeline. ASCO website. https://www.asco.org/ research-guidelines/cancer-progress-timeline. Accessed September 1, 2020.

6. Timeline of progress in immunotherapy. CRI website. www.cancerresearch.org/immunotherapy/timeline-of-progress. Accessed September 1, 2020.

7. Hoos A, Britten C. The immuno-oncology framework: Enabling a new era of cancer therapy. Oncoimmunology. 2012;1(3):334-339.